← Leaderboards
Rajgopal Govindarajan
University Of Georgia
$4,679,367
Attributed
$4,679,367
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $838.1K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,679,367 · 7
By mechanism
R01$3,694,294 · 3
R03$530,772 · 3
R15$454,301 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseBiochemicalMolecularNucleoside AnalogDrug KineticsInnovationNucleoside TransporterMouse ModelPropertyPublic HealthCessation Of LifePancreatic NeoplasmIn VivoNucleosidesMalignant Neoplasm Of PancreasFunctional DisorderPathogenesisMass Spectrum AnalysisPathway InteractionsKnockout MiceEpigenetic ProcessGrowthMalignant NeoplasmsCaring
Grant awards (21)
SLC29A3 lysosomal transporter in hematopoietic homeostasis and disease$393,750
R01 · FY2025 · HL · contact PI
SLC29A3 lysosomal transporter in hematopoietic homeostasis and disease$393,750
R01 · FY2024 · HL · contact PI
Anti-HIV NRTIs and the lysosomal toxicity$330,750
R01 · FY2024 · GM · contact PI
Anti-HIV NRTIs and the lysosomal toxicity$330,750
R01 · FY2023 · GM · contact PI
Evaluation of the antitumorigenic roles of miR-122 in pancreatic cancer$78,750
R03 · FY2023 · CA · contact PI
Anti-HIV NRTIs and the lysosomal toxicity$330,750
R01 · FY2022 · GM · contact PI
Evaluation of the antitumorigenic roles of miR-122 in pancreatic cancer$78,750
R03 · FY2022 · CA · contact PI
Anti-HIV NRTIs and the lysosomal toxicity$330,750
R01 · FY2021 · GM · contact PI
Epigenetic priming in pancreatic cancer chemotherapy$319,550
R01 · FY2018 · CA · contact PI
Epigenetic priming in pancreatic cancer chemotherapy$319,550
R01 · FY2017 · CA · contact PI
Epigenetic priming in pancreatic cancer chemotherapy$315,623
R01 · FY2016 · CA · contact PI
Epigenetic priming in pancreatic cancer chemotherapy$319,550
R01 · FY2015 · CA · contact PI
Elucidating mitochondrial pathomechanisms of ENT3 disorders in ENT3 KO mice$56,615
R03 · FY2015 · AR · contact PI
Elucidating mitochondrial pathomechanisms of ENT3 disorders in ENT3 KO mice$19,657
R03 · FY2015 · AR · contact PI
Epigenetic priming in pancreatic cancer chemotherapy$309,521
R01 · FY2014 · CA · contact PI
Nucleoside Transporter-Connexin Interplay in Pancreatic Cancer Chemotherapy$275,639
R15 · FY2014 · CA · contact PI
Nucleoside Transporter-Connexin Interplay in Pancreatic Cancer Chemotherapy$178,662
R15 · FY2014 · CA · contact PI
Elucidating mitochondrial pathomechanisms of ENT3 disorders in ENT3 KO mice$74,250
R03 · FY2014 · AR · contact PI
Elucidating mitochondrial pathomechanisms of ENT3 disorders in ENT3 KO mice$74,250
R03 · FY2013 · AR · contact PI
Epigenetic therapy with 3-deazaneplanocin A and gemcitabine for pancreatic cancer$74,250
R03 · FY2012 · CA · contact PI
Epigenetic therapy with 3-deazaneplanocin A and gemcitabine for pancreatic cancer$74,250
R03 · FY2011 · CA · contact PI